Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457248 | 0.82 | MAPK14 (0.64) | ALOX5MAPK14ADORA3ADORA1ADORA2A | |
| SCHEMBL5459554 | 0.81 | ALOX5 (0.42) | ALOX5MAPK14FYNMAPTTP53 | |
| SCHEMBL5453385 | 0.79 | MAPK14 (0.51) | ALOX5MAPK14FYNMAPTTP53 | |
| SCHEMBL5457302 | 0.79 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL5462426 | 0.78 | MAPK14 (0.43) | ALOX5MAPK14FYNADORA3ADORA1 | |
| SCHEMBL5209423 | 0.78 | ADORA3 (0.43) | MAPTADORA3ADORA1ADORA2AKDM4E | |
| SCHEMBL5456838 | 0.77 | CSNK1D (0.51) | MAPK14 | |
| SCHEMBL5454714 | 0.76 | MAPK14 (0.47) | MAPK14PIM1CSNK1E | |
| SCHEMBL5457242 | 0.76 | PTGS2 (0.45) | ALOX5MAPK14RAB9AKDM4EALDH1A1 | |
| SCHEMBL5462491 | 0.76 | CSNK1D (0.51) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | BOYD F LESLIE | 2007-12-13 | — | — | US | disclosed |
| EP-1377573-B1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287721-A1 | Pyrazolopyridinyl pyridine | CYP3A5, CYP2C19, CYP3A4 | ALOX5 2299/4885MAPK14 2533/4885FYN 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.